Japan Drug Delivery Devices Market

Japan Drug Delivery Devices Market by Route of Administrations (Ocular, Topical, Injectable, Oral, and Others), Applications (Cardiovascular, Infectious Diseases, Cancer, Diabetes, and Others), End-users (Hospitals, Ambulatory Surgical Centers, and Others), and Country - Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1376
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 3
  • No. Of Pages: 195
  • Format:
  • Pub. Date: Upcoming
  • Share:

The Japan drug delivery devices market size is projected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to decrease the chances of side effects by optimizing the drug presence at the target site. It helps in reducing the dose and associated side effects along with decreasing the product price by reducing the amount of active pharmaceutical ingredients.

Drug delivery devices are specialized tools helps to deliver drugs through various route of administration. These devices are used for treatments of various diseases. These devices can be implantable or conventional. Drug delivery devices have different features including specific therapeutic effect, high degree of safety, target specificity, dose optimization, and efficiency. Drug delivery devices control the location and rate of drug released in the body. 


Japan Drug Delivery Devices Market summary

The medications are taken in different ways such as by absorption, through the skin, by swallowing, by inhalation, and by intravenous injection. For this, drug delivery devices are used to deliver drugs in the specific device type. The drug delivery devices have changed drastically in past few decades and even greater changes are projected in the near future. Growing geriatric population in Japan and increasing adoption of biologics is expected to boost the market growth.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing prevalence of chronic diseases is anticipated to spur the market expansion during the forecast period.
  • Rapid growth of healthcare sector is major factor driving the market growth.
  • Strict government rules and regulations regarding drug delivery devices are estimated to hinder the market expansion during the forecast period.
  • Inefficiency in delivering poorly soluble drugs act as main challenge that can impede the market growth.
  • R&D investment and technological advancement in drug delivery devices are expected to offer immense opportunities for the market players.

Scope of the Report

The report on the Japan drug delivery devices market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Japan Drug Delivery Devices Market - Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Route of Administrations (Ocular, Topical, Injectable, Oral, and Others), Applications (Cardiovascular, Infectious Diseases, Cancer, Diabetes, and Others), End-users (Hospitals, Ambulatory Surgical Centers, and Others)

Country

Japan

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

GlaxoSmithKline Plc.; ANTARES PHARMA, Inc.; Novartis AG; Mylan N.V.; and Tasei Kako Co. Ltd.

 

Market Segment Insights:

Oral segment is projected to account for a large market share

Based on route of administrations, the Japan drug delivery devices market is divided into ocular, topical, injectable, oral, and others. The oral segment is expected to constitute a key share of the market during the forecast period owing to highly preferable route of administration, easy to use, and drug stability. The oral drug delivery system involves various ranges of dosage forms such as capsules, solutions, tablets, syrups, and suspensions. However, the injectable segment is anticipated to expand at a rapid pace during the forecast period due to technological advancement in injectable drug delivery system such as introduction of pen injectors and prefilled syringes.

Cancer segment is projected to hold a key market share

On the basis of applications, the market is segmented into cardiovascular, infectious diseases, cancer, diabetes, and others. The cancer segment is expected to represent a key share of the market in the coming years due to increasing prevalence of cancer and government’s initiatives to spread awareness about cancer and its treatments. On the other hand, the diabetes segment is anticipated to expand at a rapid pace during the forecast period owing to rising number of diagnosed diabetes cases.


Japan Drug Delivery Devices Market application

Hospitals segment is projected to constitute a major market share

In terms of end-users, the Japan drug delivery devices market is segregated into hospitals, ambulatory surgical centers, and others. The hospitals segment is expected to account for a key share of the market during the forecast period owing to growing cases of neurological disorders, diabetes, and cancer that requires various types of drugs for treatment. However, the ambulatory surgical centers segment is anticipated to expand at a rapid pace during the forecast period due to increasing focus on adopting and developing drug delivery devices.  


Japan Drug Delivery Devices Market end users

Segments

Segments Covered in the Report

The Japan drug delivery devices market has been segmented on the basis of

Route of Administrations

  • Ocular
  • Topical
  • Injectable
  • Oral
  • Others

Applications

  • Cardiovascular
  • Infectious Diseases
  • Cancer
  • Diabetes
  • Others

End-users

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Country

  • Japan

Key Players

  • GlaxoSmithKline Plc.
  • ANTARES PHARMA, Inc.
  • Novartis AG
  • Mylan N.V.
  • Tasei Kako Co. Ltd.

Competitive Landscape

Key players competing in the Japan drug delivery devices market include GlaxoSmithKline Plc.; ANTARES PHARMA, Inc.; Novartis AG; Mylan N.V.; and Tasei Kako Co. Ltd. Some of these players are engaged in several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.

Japan Drug Delivery Devices Market keyplayers

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Drug Delivery Devices Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Drug Delivery Devices Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Drug Delivery Devices Market - Supply Chain
  4.5. Global Drug Delivery Devices Market Forecast
     4.5.1. Drug Delivery Devices Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Drug Delivery Devices Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Drug Delivery Devices Market Absolute $ Opportunity
5. Global Drug Delivery Devices Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Drug Delivery Devices Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Drug Delivery Devices Demand Share Forecast, 2019-2026
6. North America Drug Delivery Devices Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Drug Delivery Devices Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Drug Delivery Devices Demand Share Forecast, 2019-2026
7. Latin America Drug Delivery Devices Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Drug Delivery Devices Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Drug Delivery Devices Demand Share Forecast, 2019-2026
8. Europe Drug Delivery Devices Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Drug Delivery Devices Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Drug Delivery Devices Demand Share Forecast, 2019-2026
9. Asia Pacific Drug Delivery Devices Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Drug Delivery Devices Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Drug Delivery Devices Demand Share Forecast, 2019-2026
10. Middle East & Africa Drug Delivery Devices Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Drug Delivery Devices Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Drug Delivery Devices Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Drug Delivery Devices Market: Market Share Analysis
  11.2. Drug Delivery Devices Distributors and Customers
  11.3. Drug Delivery Devices Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. GlaxoSmithKline Plc.
     11.4.2. ANTARES PHARMA, Inc.
     11.4.3. Novartis AG
     11.4.4. Mylan N.V.
     11.4.5. Tasei Kako Co. Ltd.

Segments Covered in the Report

The Japan drug delivery devices market has been segmented on the basis of

Route of Administrations

  • Ocular
  • Topical
  • Injectable
  • Oral
  • Others

Applications

  • Cardiovascular
  • Infectious Diseases
  • Cancer
  • Diabetes
  • Others

End-users

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Country

  • Japan

Key Players

  • GlaxoSmithKline Plc.
  • ANTARES PHARMA, Inc.
  • Novartis AG
  • Mylan N.V.
  • Tasei Kako Co. Ltd.

Key players competing in the Japan drug delivery devices market include GlaxoSmithKline Plc.; ANTARES PHARMA, Inc.; Novartis AG; Mylan N.V.; and Tasei Kako Co. Ltd. Some of these players are engaged in several market strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares.

Japan Drug Delivery Devices Market keyplayers

Buy Report